{
    "nct_id": "NCT03397706",
    "official_title": "A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies",
    "inclusion_criteria": "* Relapsed/refractory, pathologically confirmed Epstein-Barr Virus positive (EBV+) lymphoid malignancy or lymphoproliferative disease\n* Absence of available therapy with reasonable likelihood of cure or significant clinical benefit\n* Adequate hematologic, hepatic and renal function as defined by laboratory assessment\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known primary central nervous system (CNS) lymphoma\n* Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks\n* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Refractory graft versus host disease (GvHD) not responding to treatment\n* Known active hepatitis B virus infection\n* Circulating hepatitis C virus on quantitative polymerase chain reaction (qPCR)\n* Known history of human herpes virus (HHV)-6 chromosomal integration\n* Known history of HIV infection",
    "miscellaneous_criteria": "Key"
}